Navamedic
ISIN: NO0010205966 | Ticker: NAVA | LEI: 529900LKVQOR2SRUJU71
Country: Norway
Navamedic ASA is a Nordic pharma company with a footprint in Northern Europe.
We are a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers.
Our product portfolio consists of prescription and OTC pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics.
Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like UK and Greece. Our headquarter is in Oslo, Norway and we are listed on the Oslo Stock Exchange (ticker: NAVA).
2002
Served areaEurope
HeadquartersHenrik Ibsensgate 100, 0255 Oslo – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 260,038,000.00 | 330,179,000.00 | 382,772,000.00 |
| Noncurrent Assets | N/A | 142,249,000.00 | 124,690,000.00 | 139,233,000.00 |
| Property Plant And Equipment | N/A | 174,000.00 | 745,000.00 | 607,000.00 |
| Goodwill | N/A | 64,472,000.00 | 61,031,000.00 | 100,743,000.00 |
| Other Intangible Assets | N/A | 9,689,000.00 | 27,342,000.00 | 30,537,000.00 |
| Investments In Associates Accounted For Using Equity Method | N/A | 22,022,000.00 | 18,837,000.00 | 0.00 |
| Noncurrent Receivables Due From Associates | N/A | 34,821,000.00 | 0.00 | N/A |
| Deferred Tax Assets | N/A | 9,168,000.00 | 9,168,000.00 | 835,000.00 |
| Other Noncurrent Assets | N/A | 58,919,000.00 | 27,149,000.00 | 7,118,000.00 |
| Current Assets | N/A | 117,789,000.00 | 205,489,000.00 | 243,539,000.00 |
| Inventories | N/A | 41,945,000.00 | 61,882,000.00 | 79,642,000.00 |
| Current Receivables Due From Associates | N/A | 0.00 | 37,606,000.00 | 40,615,000.00 |
| Current Tax Assets Current | N/A | 7,614,000.00 | 15,652,000.00 | 14,909,000.00 |
| Other Current Financial Assets | N/A | N/A | 0.00 | 10,092,000.00 |
| Cash and cash equivalents | 11,439,000.00 | 39,584,000.00 | 52,620,000.00 | 55,296,000.00 |
| Equity And Liabilities | N/A | 260,038,000.00 | 330,179,000.00 | 382,772,000.00 |
| Equity | 79,231,000.00 | 129,486,000.00 | 151,237,000.00 | 209,720,000.00 |
| Issued Capital | N/A | 11,316,000.00 | 12,096,000.00 | 12,749,000.00 |
| Retained Earnings | N/A | -29,441,000.00 | -26,689,000.00 | 6,563,000.00 |
| Share Premium | N/A | 147,610,000.00 | 165,830,000.00 | 190,408,000.00 |
| Liabilities | N/A | 130,552,000.00 | 178,943,000.00 | 173,053,000.00 |
| Noncurrent Liabilities | N/A | 25,055,000.00 | 43,231,000.00 | 46,991,000.00 |
| Longterm Borrowings | N/A | 20,870,000.00 | 29,235,000.00 | 38,368,000.00 |
| Current Liabilities | N/A | 105,497,000.00 | 135,712,000.00 | 126,062,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 66,956,000.00 | 70,532,000.00 | 65,574,000.00 |
| Current Tax Liabilities Current | N/A | 2,795,000.00 | 10,713,000.00 | 4,708,000.00 |
| Other Current Liabilities | N/A | 18,168,000.00 | 29,724,000.00 | 40,071,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 209,877,000.00 | 278,439,000.00 | 382,135,000.00 |
| Raw Materials And Consumables Used | 139,538,000.00 | 166,695,000.00 | 218,615,000.00 |
| Employee Benefits Expense | 32,574,000.00 | 44,455,000.00 | 48,088,000.00 |
| Depreciation Expense | 1,551,000.00 | 2,169,000.00 | 2,392,000.00 |
| Amortisation Expense | 2,108,000.00 | 4,547,000.00 | 4,850,000.00 |
| Other Expense By Nature | 39,031,000.00 | 49,118,000.00 | 63,745,000.00 |
| Profit Loss From Operating Activities | -4,926,000.00 | 11,455,000.00 | 44,444,000.00 |
| Finance Income | 2,846,000.00 | 4,035,000.00 | 19,464,000.00 |
| Finance Costs | 3,844,000.00 | 4,424,000.00 | 3,416,000.00 |
| Profit Loss Before Tax | -16,596,000.00 | 2,358,000.00 | 42,506,000.00 |
| Income Tax Expense Continuing Operations | -136,000.00 | 1,740,000.00 | 13,074,000.00 |
| Profit (loss) | -16,460,000.00 | 618,000.00 | 29,431,000.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -16,460,000.00 | 618,000.00 | 29,431,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -9,962,000.00 | -19,937,000.00 | -17,761,000.00 |
| Adjustments For Undistributed Profits Of Associates | N/A | -4,528,000.00 | -3,185,000.00 | 8,413,000.00 |
| Other Adjustments For Noncash Items | N/A | 0.00 | 1,784,000.00 | 839,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 287,000.00 | 2,700,000.00 | 10,967,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -3,180,000.00 | -1,300,000.00 | 17,941,000.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 11,250,000.00 | 0.00 | 23,264,000.00 |
| Interest Received Classified As Investing Activities | N/A | 9,000.00 | 2,000.00 | 70,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -23,137,000.00 | -727,000.00 | -25,444,000.00 |
| Proceeds From Issuing Shares | N/A | 60,447,000.00 | 0.00 | 1,198,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 19,500,000.00 | 24,033,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 5,251,000.00 | 0.00 | 9,511,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,594,000.00 | 2,100,000.00 | 2,373,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 1,844,000.00 | 1,469,000.00 | 3,272,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 51,759,000.00 | 15,931,000.00 | 10,074,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 2,703,000.00 | -868,000.00 | 105,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 28,145,000.00 | 13,036,000.00 | 2,676,000.00 |
| Cash and cash equivalents | 11,439,000.00 | 39,584,000.00 | 52,620,000.00 | 55,296,000.00 |
Please note that some sums might not add up.
NO0010205966
LEI529900LKVQOR2SRUJU71
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.